Virax Biolabs Strengthens Board with Diagnostics Veteran Iain Miller as Company Advances Immune Profiling Platform
Key Insights
Virax Biolabs (search) has appointed Iain Miller, PhD as an Independent Director, bringing over 30 years of diagnostics and MedTech leadership experience to guide the company's strategic development.
Dr. Miller previously led Presymptom Health (search) and developed InfectiClear (search)®, a novel diagnostic for infectious diseases (search), while serving on regulatory committees including UK's NICE Technology Appraisal Committee.
The appointment comes as Virax works to expand its immune profiling platform from Research-Use-Only products toward IVD development and regulatory approval for monitoring chronic and post-viral conditions (search).
Virax Biolabs (search) Group Limited (Nasdaq: VRAX) announced the appointment of Iain Miller, PhD as an Independent Director to its Board of Directors, effective July 29, 2025. The biotechnology company, focused on detecting immune responses and diagnosing viral diseases (search), selected Dr. Miller to replace Yair Erez, who is stepping down to pursue other professional endeavors.
Extensive Diagnostics Leadership Experience
Dr. Miller brings over 30 years of leadership experience across the diagnostics and MedTech sectors, having held senior positions at major healthcare organizations including GE Healthcare, bioMérieux, and Massachusetts General Hospital. His experience spans both United Kingdom and United States markets, providing international perspective for Virax's expansion plans.
The new board member has founded and led four MedTech companies, including Presymptom Health (search), a UK Ministry of Defence spinout where he served as Chief Executive Officer. Under his leadership, Presymptom Health developed InfectiClear (search)®, a novel diagnostic for infectious diseases (search), demonstrating his capability in bringing innovative diagnostic solutions to market.
Regulatory and Academic Credentials
Dr. Miller's regulatory expertise includes service on the UK's NICE Technology Appraisal Committee and contributions to innovation programmes at NHS England (search) and the Medicines and Healthcare products Regulatory Agency (MHRA). His academic credentials include a PhD in BioEngineering from the University of Strathclyde, an MBA from the University of Edinburgh, and a BSc in Physics & Electronics from the University of Glasgow. He has published extensively on diagnostic innovation.
Strategic Timing for Platform Development
The appointment comes during a critical phase for Virax as the company works to advance its immune profiling platform beyond its initial Research-Use-Only (RUO) product rollout. According to James Foster, Chief Executive Officer of Virax Biolabs (search), Dr. Miller's "leadership across private and public sector organisations, combined with deep diagnostics expertise and international experience, will be instrumental as we work to advance our immune profiling platform — building on our initial Research-Use-Only (RUO) product rollout and progressing toward IVD development, regulatory engagement, and future market entry."
Focus on Chronic and Post-Viral Conditions
Dr. Miller expressed enthusiasm about joining the company during this strategic phase, stating: "I am excited to join the Board of Virax Biolabs (search) at a time of strategic focus and momentum. The Company's immune profiling platform presents a compelling opportunity to enhance how chronic and post-viral conditions (search) are monitored. I look forward to supporting the team in realising this vision."
The company's immune profiling platform represents a significant opportunity in the growing field of post-viral condition monitoring, an area that has gained increased attention following the COVID-19 pandemic and growing recognition of long-term viral effects on immune system function.